Akari Therapeutics, a late-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, has announced the appointment of Samir R. Patel, M.D. to its Board of Directors. Dr. Patel brings extensive experience as a life sciences entrepreneur and has a track record of success in startup companies. He is currently the founder and principal of PranaBio Investments, a firm providing consulting and investment services for small cap biotech companies. Dr. Patel’s appointment comes at a crucial time for Akari as they continue to develop their lead asset, nomacopan.
Nomacopan is an investigational bispecific recombinant inhibitor targeting complement C5 activation and leukotriene B4 (LTB4) activity. Akari is conducting a Phase 3 clinical trial program for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), and they have received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA for this indication. In addition to their work in pediatric HSCT-TMA, Akari is also exploring the use of nomacopan in adult HSCT-TMA and geographic atrophy.
Dr. Patel’s expertise in life sciences and his commitment to advancing Akari’s mission will contribute significantly to the development and success of nomacopan. His appointment reflects Akari’s dedication to bringing innovative therapies to patients with autoimmune and inflammatory diseases.
